PMID- 24467772
OWN - NLM
STAT- MEDLINE
DCOM- 20141016
LR  - 20181202
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
VI  - 11
IP  - 4
DP  - 2014 Apr
TI  - Assessment of androgen replacement therapy for erectile function in rats with 
      type 2 diabetes mellitus by examining nitric oxide-related and inflammatory 
      factors.
PG  - 920-929
LID - S1743-6095(15)30721-9 [pii]
LID - 10.1111/jsm.12447 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) has become a major public health 
      issue and is considered a risk factor for erectile dysfunction (ED). T2DM is also 
      associated with androgen deficiency. However, there have been few basic studies 
      on androgen replacement therapy (ART) for ED treatment in T2DM animal models, and 
      the mechanism underlying the effect of ART on T2DM-induced ED is unclear. AIM: To 
      investigate the effect of ART on ED in T2DM rats by examining inflammatory and 
      nitric oxide (NO)-related factors. METHODS: Otsuka Long-Evans Tokushima Fatty 
      (OLETF) rats and their controls, Long-Evans Tokushima Otsuka (LETO) rats, were 
      distributed into three groups: LETO, OLETF, and ART. In the ART group, OLETF rats 
      were treated daily with testosterone (3 mg/kg/day, subcutaneously) from 20 to 25 
      weeks of age; LETO and OLETF rats received vehicle only. MAIN OUTCOME MEASURES: 
      We measured erectile function by using measurements of the ratio between 
      intracavernosal pressure (ICP) and mean arterial pressure (MAP) following 
      electrical stimulation of the cavernous nerve and by evaluating the endothelial 
      function of the corpus cavernosum in an isometric tension study. Expression of 
      endothelial NO synthase (eNOS), inducible NO synthase (iNOS), sirtuin-1 (Sirt1), 
      interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha) mRNA was detected 
      using polymerase chain reaction. RESULTS: The ICP/MAP ratio in the OLETF group 
      was significantly decreased and that in the ART group was significantly improved 
      (P < 0.01). The response to acetylcholine was significantly decreased in the 
      OLETF group and improved in the ART group (P < 0.01). Although expression of eNOS 
      and Sirt1 mRNA was decreased and that of iNOS, IL-6, and TNF-alpha mRNA was increased 
      in the OLETF group, ART improved mRNA expression. CONCLUSIONS: ART suppressed 
      inflammation in rats with T2DM and metabolic disorders and improved their 
      endothelial and erectile functions. ART could be effective for T2DM-induced ED 
      and may be considered a potential ED treatment method.
CI  - (c) 2014 International Society for Sexual Medicine.
FAU - Kataoka, Tomoya
AU  - Kataoka T
AD  - Department of Hospital PharmacyGraduate School of Pharmaceutical SciencesNagoya 
      City UniversityNagoyaJapan.
FAU - Hotta, Yuji
AU  - Hotta Y
AD  - Department of Hospital PharmacyGraduate School of Pharmaceutical SciencesNagoya 
      City UniversityNagoyaJapan.
FAU - Maeda, Yasuhiro
AU  - Maeda Y
AD  - Department of Hospital PharmacyGraduate School of Pharmaceutical SciencesNagoya 
      City UniversityNagoyaJapan.
FAU - Kimura, Kazunori
AU  - Kimura K
AD  - Department of Hospital PharmacyGraduate School of Pharmaceutical SciencesNagoya 
      City UniversityNagoyaJapan; Department of Clinical PharmacyGraduate School of 
      Medical SciencesNagoya City UniversityNagoyaJapan. Electronic address: 
      kkimura@med.nagoya-cu.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20140128
PL  - Netherlands
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
RN  - 0 (Androgens)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (dimethylarginine)
RN  - 3XMK78S47O (Testosterone)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.13.39 (Nos3 protein, rat)
SB  - IM
MH  - Androgens/*pharmacology
MH  - Animals
MH  - Arginine/analogs & derivatives/metabolism
MH  - Diabetes Mellitus, Experimental/physiopathology
MH  - Diabetes Mellitus, Type 2/physiopathology
MH  - Electric Stimulation
MH  - Erectile Dysfunction/*drug therapy/physiopathology
MH  - *Hormone Replacement Therapy
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Nitric Oxide Synthase Type III/metabolism
MH  - Penile Erection/drug effects
MH  - Penis/metabolism
MH  - Rats, Long-Evans
MH  - Testosterone/*pharmacology
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Androgen Replacement Therapy
OT  - Endothelial Dysfunction
OT  - Erectile Dysfunction
OT  - Inflammation
OT  - Obesity
OT  - Testosterone
OT  - Type 2 Diabetes Mellitus
EDAT- 2014/01/29 06:00
MHDA- 2014/10/17 06:00
CRDT- 2014/01/29 06:00
PHST- 2014/01/29 06:00 [entrez]
PHST- 2014/01/29 06:00 [pubmed]
PHST- 2014/10/17 06:00 [medline]
AID - S1743-6095(15)30721-9 [pii]
AID - 10.1111/jsm.12447 [doi]
PST - ppublish
SO  - J Sex Med. 2014 Apr;11(4):920-929. doi: 10.1111/jsm.12447. Epub 2014 Jan 28.